This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
COL5A3 / Collagen alpha-3(V) chain · IHC design guide
Design Immunohistochemistry for COL5A3
Plan COL5A3 staining in paraffin sections with the catalog antibody at 1:100–1:300 (datasheet). Use cervical squamous epithelium as a high-staining reference (HPA tissue IHC), and interpret cytoplasmic staining alongside COL5A3’s secreted extracellular location (HPA tissue IHC; UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
COL5A3 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Observed cytoplasmic staining (HPA tissue IHC); secreted extracellular matrix location (UniProt) | |
| Staining pattern | Cytoplasmic staining in squamous and glandular cells (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Cervix+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific) | |
| Caveat | As a secreted protein, staining may differ from the tissue RNA pattern (HPA tissue IHC) | |
| Regulation | No specific regulator documented in the supplied record (UniProt) | |
| Isoform / epitope | No isoforms listed; the mature chain begins at residue 30 (UniProt) |
Section 1
Recommended COL5A3 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is paired with one published COL5A3 IHC workflow (PMC10891384).
| Sample | Paraffin-embedded human breast carcinoma tissue; fixative not specified (datasheet A10525) |
| Fixation | Image fixative and duration unreported (datasheet A10525); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-COL5A3, 1:100-1:300 (datasheet A10525) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | COL5A3-positive staining in squamous epithelial cells of cervix (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic expression. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 HIER at 95–98 °C for 20 min (page retrieval); the published workflow uses microwave retrieval for 25 min (PMC10891384).
Section 2
What Is the Expected COL5A3 Staining Pattern?
COL5A3 is a secreted, extracellular matrix collagen with no transmembrane segment (UniProt P25940 localization and topology). In tissue IHC, HPA reports a general cytoplasmic pattern, including strong staining in selected squamous epithelial, glandular, and Leydig cells (HPA tissue IHC). Treat these as observed patterns rather than definitive localization: HPA rates the IHC evidence Approved but reports low agreement with RNA data and pending external verification (HPA tissue IHC reliability).
| Strong cytoplasmic staining in cervical or tonsillar squamous epithelial cells, parathyroid or small-intestinal glandular cells, or testicular Leydig cells (HPA tissue IHC). | These are HPA High cell-specific observations (HPA tissue IHC). Score the named cells and their surrounding tissue separately; secreted COL5A3 can occupy extracellular space after synthesis (UniProt P25940 localization). |
| Staining appears predominantly nuclear, with little signal in the expected cells. | A nuclear-dominant pattern conflicts with HPA's general cytoplasmic tissue profile and UniProt's secreted extracellular annotation (HPA tissue IHC; UniProt P25940 localization). Check background and antibody specificity before calling it COL5A3. |
| Strong signal appears in adipocytes, lung alveolar cells, or prostate glandular cells while the selected positive control also stains. | HPA reports these particular cell populations as Not detected (HPA tissue IHC). Consider cross-reactivity or endogenous detection activity; a positive control does not establish that every stained cell is specific (general IHC practice). |
| Chromogen covers many cells and extracellular areas uniformly, obscuring cell boundaries and tissue structure. | A uniform haze cannot be scored against HPA's cell-specific levels (HPA tissue IHC). Nonspecific antibody binding or detection background is possible; compare a no-primary control and inspect unaffected areas (general IHC practice). |
| No signal appears in a run containing a previously confirmed positive tissue section. | First treat this as an assay failure if the run control also lacks signal (general IHC practice). HPA High tissue observations are useful comparators, but HPA's Approved rating includes low RNA–staining consistency and pending external verification (HPA tissue IHC reliability). |
💡Expected COL5A3 appearanceCall a positive result when chromogen is discernible in the HPA High cell populations, typically with a cytoplasmic tissue profile; assess any extracellular signal in light of secretion, and question isolated nuclear or uniform tissue-wide staining (HPA tissue IHC; UniProt P25940 localization; general IHC practice).
| Compartment and secretion | UniProt places COL5A3 in extracellular space and matrix and lists no transmembrane segment (UniProt P25940 localization and topology). HPA nevertheless describes general cytoplasmic tissue staining (HPA tissue IHC); use both annotations when interpreting a section. |
| Cell-specific reference levels | HPA reports High staining in selected squamous epithelial, glandular, and Leydig cells; Medium in adrenal, appendix, and breast glandular cells (HPA tissue IHC). These levels describe sampled cell populations, not every cell in each organ. |
| Reliability of tissue comparisons | HPA assigns Approved reliability but notes low agreement between antibody staining and RNA expression, as expected for a secreted protein; external verification is pending (HPA tissue IHC reliability). Avoid using RNA location alone to reject a protein signal. |
| Antibody-specific validation | The supplied HPA antibody records list IHC Approved for HPA048256 and ICC Approved for HPA041695, with no IHC rating for the latter (HPA antibodies). Match an image or control to the relevant assay before transferring its interpretation. |
| Processing and epitope scope | UniProt annotates a signal peptide at residues 1–29 and a chain at 30–1745 (UniProt P25940 processing). The supplied sources do not locate the IHC antibody epitope, so they cannot establish which molecular pool it detects. |
| Does IF/ICC predict the IHC pattern? | HPA reports approved plasma-membrane localization in ICC-IF, while its tissue IHC profile is generally cytoplasmic (HPA subcellular ICC-IF; HPA tissue IHC). Interpret each assay with its own reference image and validation status. |
| Situation | Likely cause | Next action |
|---|---|---|
| The positive control and study sections are blank. | A run-wide staining or detection failure is possible (general IHC practice). | Check control integrity, primary-antibody application, detection reagents, and chromogen development; repeat alongside a previously confirmed positive section (general IHC practice). |
| The control stains, but the study section is blank. | COL5A3 may be absent from the sampled cells; HPA lists several cell populations as Not detected (HPA tissue IHC). | Record the exact cell population, compare it with HPA's cell-level entries, and assess a suitable positive population in the same run (HPA tissue IHC; general IHC practice). |
| Signal is diffuse across the section. | Nonspecific binding or detection background may obscure a cell-specific pattern (general IHC practice). | Compare a no-primary control; review blocking, washing, antibody concentration, and detection conditions before scoring (general IHC practice). |
| Unexpected cells stain strongly. | Cross-reactivity or endogenous detection activity is possible, especially when HPA reports those cells as Not detected (HPA tissue IHC; general IHC practice). | Check a no-primary control for detection background, review the stained cell identity, and seek an independent specificity check before assigning COL5A3 (general IHC practice). |
| Only nuclei show strong staining. | This differs from the reported cytoplasmic tissue profile and secreted localization (HPA tissue IHC; UniProt P25940 localization). | Inspect the no-primary control and staining distribution; verify antibody specificity before treating nuclear signal as a new localization (general IHC practice). |
| An ICC-IF image appears membrane-associated, but the tissue section looks cytoplasmic. | HPA reports plasma-membrane localization for ICC-IF and a general cytoplasmic profile for tissue IHC (HPA subcellular ICC-IF; HPA tissue IHC). | Compare each result with its own assay reference and record cell identity and compartment separately; do not force identical scores across assays (HPA subcellular ICC-IF; HPA tissue IHC). |
Experiment evidence
IHC & IF images showing COL5A3 staining
A10525 · IHCImmunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using Collagen V alpha3 Antibody. The picture on the right
A10525 · IFImmunofluorescence analysis of HeLa cells, using Collagen V alpha3 Antibody. The picture on the right is blocked with the synthesized peptid
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000080573-COL5A3/tissue/cerebral+cortex#imid_14501752
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000080573-COL5A3/tissue/colon#imid_14581147
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000080573-COL5A3/tissue/liver#imid_14581146
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000080573-COL5A3/tissue/kidney#imid_14581151
HPA · ICC-IF ASC52teloHuman Protein Atlas immunofluorescence, ASC52telo, antibody HPA041695; green = COL5A3, blue = nucleus, red = microtubules.
HPA · ICC-IF ASC52teloHuman Protein Atlas immunofluorescence, ASC52telo, antibody HPA041695; green = COL5A3, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for COL5A3 IHC & IF
🧪Run cervix first and assess squamous epithelial cells, which HPA rates High for COL5A3 (HPA: High in cervical squamous epithelial cells). Use endometrial stromal cells as the negative tissue comparator (HPA: Not detected in endometrial stromal cells); on the cervical slide, use any unstained non-squamous cells as internal background comparators without assuming they are biologically negative (HPA: cervical squamous epithelial cells are the listed positive compartment).
Positive control tissue: Cervix (Squamous epithelial cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show COL5A3 in ASC52telo, BJ [Human fibroblast], U2OS, with annotated localisation: Plasma membrane (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and an isotype control matched to the primary antibody’s host species and clonality; use a knockout specimen or peptide competition as a biological specificity control (standard IHC practice; A10525 caption: peptide-blocked image). For chromogenic IHC, block endogenous peroxidase and check for endogenous biotin if using avidin–biotin detection (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the A10525 paraffin-section breast carcinoma caption does not state the fixative (A10525 caption). Antigen retrieval dependency is unreported, and the supplied evidence does not establish whether frozen sections or IF are easier (A10525 caption; HPA subcellular: ICC-IF images available). When scoring cervical squamous epithelium, check section edges for staining artefact and distinguish extracellular matrix signal from cell-associated signal (standard IHC practice; UniProt P25940: secreted extracellular matrix protein).
HPA tissue IHC evidence for COL5A3
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data. Secreted protein, tissue location of RNA and protein is expected to differ. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cervix | Squamous epithelial cells | High | Protein (IHC) | HPA → |
| Parathyroid gland | Glandular cells | High | Protein (IHC) | HPA → |
| Small intestine | Glandular cells | High | Protein (IHC) | HPA → |
| Testis | Leydig cells | High | Protein (IHC) | HPA → |
| Tonsil | Squamous epithelial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Endometrium | Cells in endometrial stroma | Not detected | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Hippocampus | Glial cells | Not detected | Protein (IHC) | HPA → |
| Lung | Alveolar cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced COL5A3 IHC Tips
Troubleshoot COL5A3 staining in paraffin sections by checking retrieval, compartment, controls, and scoring against the available tissue evidence.
How should I adjust retrieval when COL5A3 staining is weak or uneven?
Start with citrate buffer at pH 6.0 for heat-induced retrieval at 95–98 °C for 20 min (page retrieval setting). Run a positive control alongside the test section, and keep section thickness, heating, and cooling consistent before changing conditions (standard IHC practice). If staining remains weak, compare a second retrieval condition on adjacent sections while keeping antibody concentration and detection constant (standard IHC practice). Score epithelial and extracellular staining separately, because HPA reports general cytoplasmic staining whereas UniProt places secreted COL5A3 in the extracellular matrix (HPA tissue IHC; UniProt P25940). Excessive retrieval can damage morphology and make compartment assignment unreliable (standard IHC practice).
Can fixation explain variable COL5A3 staining between paraffin blocks?
Target-specific fixation sensitivity is unknown: the selected tissue caption identifies paraffin-embedded breast carcinoma but does not state a fixative (A10525 tissue-IHC caption). Record each block’s fixative and fixation duration, then compare similarly processed sections with the same retrieval and detection settings (standard IHC practice). If results differ, inspect morphology and staining in a control section from each processing batch before attributing the difference to COL5A3 abundance (standard IHC practice). Avoid assigning a fixation effect from HPA staining patterns or COL5A3 topology and glycosylation, which do not establish fixation sensitivity (HPA tissue IHC; UniProt P25940).
Should COL5A3 staining be cytoplasmic, membranous, or extracellular?
Evaluate compartments separately: UniProt places COL5A3 in the extracellular space and matrix, while HPA tissue IHC describes general cytoplasmic expression (UniProt P25940; HPA tissue IHC). HPA subcellular IF reports an approved plasma-membrane location, so a membrane-associated signal also deserves review against tissue morphology (HPA subcellular). Compare cell borders and matrix-rich areas at the same illumination and counterstain settings, using adjacent sections when boundaries are unclear (standard IHC practice). Treat a solely nuclear signal as discordant with the reported locations and check antibody-independent background and the peptide-blocked control before interpreting it (UniProt P25940; HPA subcellular; A10525 tissue-IHC caption).
How can epitope accessibility complicate COL5A3 IHC interpretation?
The supplied UniProt record lists 0 isoforms and a signal peptide at residues 1–29, followed by the collagen chain at 30–1745 (UniProt P25940). It also lists glycosylation sites at residues 102, 141, and 349 and multiple collagen-like regions, but the antibody epitope is unspecified here (UniProt P25940; A10525 tissue-IHC caption). Therefore, do not assign a weak stain to a particular modified site or domain without an epitope map (UniProt P25940; standard IHC practice). Compare matched sections under one retrieval condition and use the caption’s peptide-blocked image as specificity context, while assessing whether matrix and cellular signals change together (A10525 tissue-IHC caption; standard IHC practice).
How should I investigate COL5A3 localisation with a secondary IF experiment?
For IF, multiplex COL5A3 with a validated fibroblast marker, since COL5A3 protein has been detected in fibroblasts (UniProt P25940). Choose a fluorophore in a channel with low measured tissue autofluorescence, and collect single-channel controls before assessing overlap (standard IF practice). Determine whether the antibody epitope is accessible extracellularly or requires intracellular access before adding detergent permeabilisation; the epitope side is not specified in the supplied evidence (A10525 tissue-IHC caption; standard IF practice). Compare any membrane-associated or extracellular pattern with HPA’s plasma-membrane IF annotation and UniProt’s secreted matrix annotation, without treating their apparent difference as proof of an IF artefact (HPA subcellular; UniProt P25940).
What should I check when COL5A3 DAB staining looks diffuse?
First compare the stained section with a no-primary control and inspect whether pigment persists independently of the primary antibody (standard chromogenic IHC practice). Apply an endogenous peroxidase block before peroxidase-based detection, and assess DAB development on matched sections with the same incubation time (standard chromogenic IHC practice). The selected paraffin tissue image includes a synthesized-peptide-blocked comparison, which can help judge antibody-dependent staining for that image but does not establish every compartment’s identity (A10525 tissue-IHC caption). Because UniProt describes extracellular COL5A3 and HPA reports cytoplasmic tissue staining, document where diffuse signal lies before changing antibody concentration or calling it background (UniProt P25940; HPA tissue IHC).
How should I score COL5A3 when cells and matrix both stain? ⚠ ANSWER MARKED FOR VERIFICATION
Define cell-associated and extracellular regions before scoring, because reported COL5A3 locations include HPA’s cytoplasmic tissue pattern and UniProt’s extracellular matrix location (HPA tissue IHC; UniProt P25940). For cell-associated staining, record the percentage of positive cells and an H-score from intensity categories; normalise counts to eligible cells in the annotated compartment (standard IHC scoring practice). For matrix staining, measure positive area or optical density per mm² of viable annotated tissue and keep threshold, counterstain, and imaging settings fixed (standard image-analysis practice). Report the two measures separately, and exclude folds, tissue edges, and necrotic regions from both denominators (standard IHC scoring practice).
What distinguishes convincing COL5A3 staining from an IHC artefact?
A convincing result follows tissue structure, recurs in comparable sections, and weakens in a relevant antibody-control comparison; the selected image provides a synthesized-peptide-blocked example (standard IHC practice; A10525 tissue-IHC caption). Interpret cell-associated and matrix signal separately because HPA describes general cytoplasmic staining while UniProt identifies a secreted extracellular-matrix protein (HPA tissue IHC; UniProt P25940). Check isolated nuclear signal, tissue-edge enhancement, necrotic debris, and persistent staining after a no-primary control for localisation or detection artefacts (UniProt P25940; standard IHC practice). HPA marks its tissue IHC as Approved but notes low agreement with RNA and pending external verification, so a positive stain alone cannot establish cell-specific expression (HPA tissue IHC).
Boster reagents
Best COL5A3 / Collagen alpha-3(V) chain IHC Antibodies
A10525 has human IHC and IF images: paraffin-embedded breast carcinoma tissue and HeLa cells, respectively (catalog reactivity; A10525 IHC and IF image captions).
Real IHC data
Anti-Collagen alpha-3(V) chain COL5A3 Antibody
Cat # A10525
The A10525 card shows IHC staining of paraffin-embedded human breast carcinoma tissue with a peptide-blocked comparison (A10525 IHC image caption). Its IF image shows HeLa cells with a peptide-blocked comparison (A10525 IF image caption).
Which to pick: Choose A10525 for paraffin-section tissue IHC, starting within 1:100–1:300 (A10525 IHC image caption; datasheet: 1:100–1:300); the caption does not report the fixative (A10525 IHC image caption). For cellular IF, choose A10525, a rabbit polyclonal antibody listed for IF at 1:200–1:1000; its HeLa-cell image supports IF use, while ICC-specific validation is unreported (catalog host, clonality, applications and dilution; A10525 IF image caption). For cross-species samples, no SKU in the catalog has documented nonhuman reactivity (catalog reactivity: Human).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P25940 (CO5A3_HUMAN, Collagen alpha-3(V) chain).
- Human Protein Atlas. COL5A3 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. COL5A3 subcellular location (ICC-IF): Localized to the plasma membrane..
- Human Protein Atlas. COL5A3 antibody validation summary (2 antibodies).
- Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes. Journal of immunology research 2022 — PMC9018183.
- Systematic establishment and verification of an epithelial-mesenchymal transition gene signature for predicting prognosis of oral squamous cell carcinoma. Frontiers in genetics 2023 — PMC10447895.
- Identifying endoplasmic reticulum stress-related genes as new diagnostic and prognostic biomarkers in clear cell renal cell carcinoma. Translational andrology and urology 2024 — PMC10891384.
- PubMed PMID:10722718 — UniProt-cited evidence.
- PubMed PMID:15057824 — UniProt-cited evidence.
- PubMed PMID:1571108 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for COL5A3 (Collagen alpha-3(V) chain). Expected localisation Observed cytoplasmic staining (HPA tissue IHC); secreted extracellular matrix location (UniProt). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A10525 at 1:100-1:300 (the product's own IHC validation image is shown). Controls (HPA): positive Cervix (Squamous epithelial cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast carcinoma tissue; fixative not specified (datasheet A10525); 2. Fixation: Image fixative and duration unreported (datasheet A10525); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-COL5A3, 1:100-1:300 (datasheet A10525); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific); Caveat: As a secreted protein, staining may differ from the tissue RNA pattern (HPA tissue IHC); Isoform / epitope: No isoforms listed; the mature chain begins at residue 30 (UniProt); Regulation: No specific regulator documented in the supplied record (UniProt). Evidence: UniProt P25940, HPA tissue IHC · Approved, HPA ICC-IF · plasma membrane., Datasheet A10525, PMC10891384. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/COL5A3/immunohistochemistry-ihc-guide.